Typical Evaluation Protocols


Statements contained within this site have not been evaluated by the United States Food and Drug Administration. Any products discussed within this site are not intended to diagnose, treat, cure or prevent any disease.

Response Code:

Catagory 1: Allergies
  • Typical dose: 5 ml.
  • Typical admiinistrations per day: 2
  • Typical interval to initial response 1 - 3 days.
  • Typical interval to benefit plateau: 3 - 7 days.
  • Typical response code: 2 - 3. No reduction or elimination of other therapeutics until justified by patient's condition.

Catagory 2: Arthritis

  • Typical dose: 5 ml.
  • Typical admiinistrations per day: 2
  • Typical interval to initial response 7 - 21 days.
  • Typical interval to benefit plateau: 42 - 56 days.
  • Typical response code: 2 - 3. No reduction or elimination of other therapeutics until justified by patient's condition.

Catagory 3: Benign Prostatic Hyperplasia

  • Typical dose: 5 ml.
  • Typical admiinistrations per day: 2
  • Typical interval to initial response 7 - 14 days.
  • Typical interval to benefit plateau: 14 - 28 days.
  • Typical response code: 2 - 3. No reduction or elimination of other therapeutics until justified by patient's condition.
Catagory 4: Cancer (adjunctive use only)
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 7 - 14 days.
  • Typical interval to benefit plateau: not available.
  • Typical response code: Noticeable improvement in overall condition. No modification to treatment protocol.
Catagory 5: Celiac Sprue
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 5 days.
  • Typical interval to benefit plateau: 5 days.
  • Typical response code: 2 - 4. No relaxation of dietary restrictions should be made before day 4. Normalization of diet should not become permanent unless blood tests return negative for all antigens.
Catagory 6: Crohn's Disease
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 7 - 14 days.
  • Typical interval to benefit plateau: 42 - 56 days.
  • Typical response code: 2 -4. No reduction or elimination of other therapeutics until justified by patient's condition.
Catagory 7: Diabetes Type II
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 1 - 7 days.
  • Typical interval to benefit plateau: 14 - 28 days.
  • Typical response code: 2 - 3. No reduction or elimination of other therapeutics until justified by patient's condition
Catagory 8: Hypertension
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 7 days.
  • Typical interval to benefit plateau: 28 - 56 days.
  • Typical response code: 2 - 3. No reduction or elimination of other therapeutics until justified by patient's condition
Catagory 9: Lupus (discoid & systemic)
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 7 - 14 days.
  • Typical interval to benefit plateau: 28 - 58 days.
  • Typical response code: 2 -3. No reduction or elimination of other therapeutics until justified by patient's condition.
Catagory 10: Multiple Sclerosis
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 7 - 28 days.
  • Typical interval to benefit plateau: 28 - 180 days.
  • Typical response code: 2 - 3. No reduction or elimination of other therapeutics until justified by patient's condition.
Catagory 11: Perthes Disease (active)
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 1 - 2 days.
  • Typical interval to benefit plateau: 7 - 28 days.
  • Typical response code: 3 - 4. No reduction or elimination of other therapeutics until justified by patient's condition.
Catagory 12: Premenstrual Syndrome & Endometriosis
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 1 - 2 days.
  • Typical interval to benefit plateau: 14 days.
  • Typical response code: 2 - 4. Use of Cytolog may be limited to post ovulation period.
Catagory 13: Prion Diseases (Kuru & Creutzfeld-Jakob Syndrome)
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 12 - 28 days.
  • Typical interval to benefit plateau: 28 - 56 days.
  • Typical response code: 2 - 3. No reduction or elimination of other therapeutics until justified by patient's condition
Catagory 14: Psoriasis
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 3 - 7 days.
  • Typical interval to benefit plateau: 14 -28 days.
  • Typical response code: 2 - 3. No reduction or elimination of other therapeutics until justified by patient's condition.
Catagory 15: Sjogren's Syndrome
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 7 - 14 days.
  • Typical interval to benefit plateau: 14 - 28 days.
  • Typical response code: 3 - 4. No reduction or elimination of other therapeutics until justified by patient's condition.
Catagory 16: Spinal Muscular Atrophy
  • Typical dose: 5 ml.
  • Typical administrations per day: 2.
  • Typical interval to initial response: 7 - 14 days.
  • Typical interval to benefit plateau: 180 days.
  • Typical response code: 1 - 2. Increased consumption of water should be encouraged in adult patients
  • Catagory 17: Thrombocytopenia (ideopathic & autoimmune)
    • Typical administrations per day: 2
    • Typical interval to initial response: 1 - 2 days
    • Typical interval to benefit plateau: 4 - 10 days
    • Typical response code: 3 - 4. No reduction or elimination of other therapeutics until justified by patient's condition
    Catagory 18: Topical applications (burns, infections, insect bites, diaper rash & herpetic lesions)
    • Typical method of administration: Spray or apply with a sterile pad to affected area.
    • Typical administrations per day: 3 - 5 as needed.
    • Typical interval to initial response: 4 - 24 hours.
    • Typical interval to benefit plateau: Variable with condition.
    • Typical response code: 3 - 4. Typical observations include accelerated healing and reduced tendency to scar.
    Catagory 19: Acute Viral Infections
    • Typical dose: 5 - 10 ml.
    • Typical administrations per day: 2 - 3.
    • Typical interval to initial response: 4 - 24 hours.
    • Typical interval to benefit plateau: 2 - 7 days.
    • Typical response code: 3 - 4. No reduction or elimination of other therapeutics until justified by patient's condition.
    Catagory 20: Chronic Viral Infections
    • Typical dose: 2.5 - 5 ml.
    • Typical administrations per day: 3 - 4.
    • Typical interval to initial response: 7 - 14 days.
    • Typical interval to benefit plateau: 28 - 90 days.
    • Typical response code: 2 - 4.

    As a general rule, the prognosis for those who benefit from the supplementation of infopeptides will be defined by the extent of permanent preexisting tissue change or damage.

    The above protocols were selected with the intent to demonstrate the range of conditions that may naturally respond to the supplementation of Infopeptides.

    Representations of fact made in association with the Cellogic Project Invitation to Physicians and Health Professionals are those of the Cellogic Project Director.

     

    ©2006 Lifestar... the art of healing. Cytolog™ and Infopeptide™ are trademarks of Cellogic Corporation. All rights reserved.